If the treatment is introduced it should be applied for patients who have been slightly or moderately affected, while more serious cases should be offered alloplastics.
Introduction of the treatment in hospitals would imply - besides an investment of 900,000 DKK for drug expenses - half a permanent post for a nurse and half a permanent post for a junior doctor, corresponding to a total expense of around 1,200,000 DKK.
The consequences of introducing the treatment in private practices should be the subject of a thorough political discussion and further clarification before this solution is chosen.
It should be considered whether it is appropriate to wait for the results from the Glostrup study before it is finally decided if Hyalgan should be offered to patients with Osteoarthritis.